"Emerging Obesity Treatments: Lilly's Record-Breaking Entry and the Mystery of Mounjaro vs. Zepbound"

Eli Lilly's stock (LLY) is forming a new flat base after the FDA approved its weight-loss drug, Zepbound. The drug is being offered at a 20% discount compared to its rival, Wegovy, which could drive better insurance coverage and patient uptake. Despite supply constraints, analysts expect Eli Lilly's weight-loss drug sales to increase significantly. The company is also working on other late-stage assets, including an Alzheimer's treatment and an eczema drug. Eli Lilly's stock has a strong performance rating and recently joined SwingTrader.